BPCOSMEDI is company for cosmetics distribution of BIOPID.

PLC-101 is the main ingredient of the ATOBEST lineup and this patented ingredient is developed by the BioPid Corporation.

After long term study and research, the company developed a specialized care product effective on atopy, sensitive and super dry skin.

The patented ingredient’s natural phospholipid vitalizes the fat metabolism beneath the skin to help rejuvenate damaged skin.

Unlike the Ceramide-like moisturizing ingredients which are used to temporarily stabilize the skin, PLC-101 will vitalize the skin cells to produce Ceramide on its own to rejuvenate damaged skin.

Marketing Concept

1. Safe to use

The patented compound of BioPid, the double saturated phospholipid used in the medication was proven to be safe through clinical trials.

2. Skin rejuvenation

The patented compound double saturated phospholipid helps the skin produce Ceramide on its own to rejuvenate damaged skin.

3. Low skin irritation

By using safe basic materials and a minimum amount of recipes, the product enables a minimum irritation level on atopy and sensitive skin.

4. Technical skills recognized World wide

Registered patent for countries in Korea, Austria, Singapore, China, Japan, Russia India, Hong Kong and EU. Application for patents applied in the U.S, Canada, Brazil.

5. KFDA’s phase 3 Clinical trial completed

Is the first Korean atopy medication to have completed phase 3 clinical trials at 8 university hospitals including Seoul Univ. Hospital, Yeonsei Univ. Severance Hospital, Catholic Univ. St. Mary’s Hospital, and Hanyang Univ. Hospital.

6. KFDA Registered medication

On March 30th, 2011, the medication is the 17th new medication to be listed on KFDA’s new medication registration.

Product Concept

1. Applies direct effect to atopy diseased, sensitive and super dry skin.

2. Forming powerful skin protection layers to create stable conditions under outside irritation.

3. Supplies basic ingredients for Ceramide production.

4. Outstanding moisture keeping ability helps keep skin moist.

5. Very stable against lipid oxidation providing outstanding skin protection.

6. Vitalizing fat metabolism of skin cells allowing smooth and shiny skin to be maintained.

BIOPID Introduction

Biopid Corporation is a bio company that was established in December 2005 for the purposes of research and development of skin disease such as atopic dermatitis, eczema, psoriasis and lung disease such as rhinitis, asthma etc.

Biopid has developed novel and effective materials on atopic dermatitis

It is a composition, *Composition for reducing the exudation of serum proteins* of which a key ingredient is the double-saturated phospholipid developed for treatment of rhinitis, asthma, chronic obstructive pulmonary diseases and noninfectious skin diseases such as atopic dermatitis and the patent registration has been completed in 17 countries of the world.

It was approved phase 2 and 3 clinical trials as a treatment for atopic dermatitis by KFDA, and it was completed clinical trials (three-phase) at 8 Korean university hospitals for the first time in Korea in 2009.

KT&G101 acquired approval of new drugs (KFDA) in nov. 2012

Also, Biopid has completed the development of cosmetics for atopic dermatitis applying the patented ingredient.

Currently, it is developing functional cosmetic for anti-aging and infant.

Biopid has a capital US$3.5M and affiliated companies, company for cosmetics distribution , for atopic medical tourism.

Atopy Medication Development History

Feb. 2005. Application of patent for *Composition for reducing blood protein exudation*

Dec. 2006. Signed transfer of technology contract with KT&G for Atopic dermatitis medication

Aug. 2008. Phase 2 and 3 of clinical trials for Atopic dermatitis medication (KT&G101) approved by Korean Food and Drug Administration

Jan. 2009. Initiation of KT&G 101 phase 2 and 3 clinical trials at 8 Korean university hospitals (Seoul University Hospital, Yeonsei University Severance Hospital, Catholic University of Korea Uijeongbu St. Mary Hospital, Hanyang University Hospital, Chungang University Hospital, Catholic University of Korea Incheon St. Mary Hospital. Hallym University Medical Center, Soonchunyang University Hospital)

Nov. 2009. Completion of Phase 3 clinical trials of Atopic dermatitis medication (KT&G101)

Jul. 2010. Composition of final report of clinical trial of Atopic dermatitis medication (KT&G101)

Mar. 2011. Applied for NDA of Atopic dermatitis medication (KT&G101) at Korean Food & Drug Administration

Nov. 2012 KT&G101 acquired approval of new medicine for Atopic Dermatitis (KFDA)

Patent Status

*Composition for reducing the exudation of serum proteins* patent

- Applicable field : Atopic dermatitis, nasal inflammation, and asthma medication and cosmetics

- Patent registration : Korea (2009), Austria, Singapore, Russia (2010), China, EU (2011), Japan, India, Hong Kong (2012)

- Patent evaluation : U.S, Brazil, Canada

*Compound for accelerating hair growth* applied for patent

- Applicable field : Hair loss prevention / hair growth

- Patent application complete (May, 2010)

- PCT application (May, 2011)

*Patch for the treatment and relief of symptoms of skin diseases with the exudation of serum proteins* applied for patent

- Applicable field : Atopic dermatitis, Eczema, Psoriasis, Erythema, Urticaria

- Patent application complete (Jul, 2010)

- PCT application (Jul, 2011)

ATOBEST PLC-101-F (For Face, 30ml)

※ Instructions

Apply an optimum amount of “PLC-101F” to atopy and damaged skin areas and to ensure better application, please massage the area for 15-20 seconds (2-3 times a day/ 1 drop per 4cm*4cm skin area recommended)

※ Please use under these circumstances!

1.When your face feels tight after washing     

2. When skin is rough and loses luster  

3. When skin peels and make up doesn’t apply well     

4.When skin doesn’t feel smooth  

5. When skin is red and swollen    

6.When the edge of the lips are dry and irritated

※ Please check when using!

1. When the area is damaged by scratching or unhealthiness, please treat the skin first before using. If used without treatment, the condition may worsen.
2. When the skin is damaged by IPL, mole removal, or laser surgery, please use the product 3-5 days after surgery.
3. When using around your eye, please avoid applying directly and apply to 1 cm below the eye.
4. When the applied area swells up due to misuse of the product, please stop applying the product and wash the area several times with warm water. This will allow the skin to return to its normal state.

※ Caution

Using the optimum amount will have a significant effect on the skin. Using more than an optimum amount may cause adverse effects.